SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Street who wrote (528)10/29/1998 2:52:00 PM
From: Gerald Walls  Read Replies (2) of 857
 
Why?

Because it's total spin. It smells bad. It makes the company smell bad.

That the company feels the way to defend itself is to draw a very dubious connection between Asensio, who would profit from stock they shorted on the open market, and stock promotion schemes, where the newsletters were paid in stock or options to print favorable articles in their newsletters without disclosing the payments, IMHO smacks of dishonest management.

I find this level of innuendo in an official company PR to be bothersome. A granted interview is "caught on tape?" I find it amusing that HEB says Asensio's "scheme" has failed because the stock is up 66% off its low, especially since it's far less impressive but just as truthful to say that the stock is about even since the short recommendation and down about 15% from the intraday high since then. They seem to be almost desperate to get the stock price up right now.

I wouldn't do a handshake deal with either Asensio or HEB, that's for sure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News